Swiss pharmaceutical firm Roche said on Tuesday that a phase II clinical trial of its experimental obesity drug CT-388, a ...

Meet Elcella - the buzzy new supplement people are calling the 'natural Mounjaro'. It promises to tame your appetite by ...

The cash injection will also allow Corxel to start phase 2 testing in type 2 diabetes and help to fund a phase 3 programme in ...

Corxel Pharmaceuticals Ltd. completed a $287 million series D round to advance its lead compound, an oral small-molecule GLP-1 receptor agonist, CX-11, for obese and overweight patients. Headquartered ...

A new study published in Otolaryngology–Head and Neck Surgery reveals that glucagon-like peptide-1 receptor agonists ...

USA: Therapy with glucagon-like peptide-1 receptor agonists (GLP-1RAs) after heart transplantation was associated with ...

According to a November poll from the Kaiser Family Foundation, one in eight Americans reported taking a GLP-1 drug, which ...

At the heart of this conversation is beta-glucan, a soluble fibre that makes oats common in nutrition circles.

Series D1 financing with participation from a syndicate of global healthcare-focused investors, including RTW Investments, SR One Capital ...

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Epidemiological evidence indicates that MASLD is associated with an ...

The landscape of weight management has evolved dramatically in recent years, with GLP-1 receptor agonists like Semaglutide leading the way in treating obesity. However, a new contender has emerged: ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH ...